OS Therapies

OSTXPhase 1

New York, United StatesFounded 2020ostherapies.com

OS Therapies is dedicated to revolutionizing cancer treatment by developing innovative immunotherapies for aggressive, underserved cancers. Its core technology platform includes OST-HER2, a novel immunotherapy that targets HER2 to induce a broad anti-tumor T-cell response, and the OST-tADC platform, a next-generation tunable antibody-drug conjugate system. The company is strategically focused on first addressing the urgent unmet need in osteosarcoma before expanding into other HER2-positive cancers such as breast, colorectal, and pancreatic cancers.

Market Cap

$54.2M

Founded

2020

Focus

Small Molecules

OSTX · Stock Price

USD 1.540.97 (-38.65%)

Historical price data

AI Company Overview

Technology Platform

A dual-platform approach featuring OST-HER2, a novel immunotherapy that activates T-cells against HER2-expressing tumors, and OST-tADC, a tunable antibody-drug conjugate platform with a proprietary silicone linker for optimized drug delivery.

Opportunities

The primary opportunity is addressing the 30+ year treatment gap in osteosarcoma, with potential for orphan drug designation and premium pricing.

Successful proof-of-concept could enable rapid expansion into large, established markets for HER2-positive breast, colorectal, and other solid tumors, leveraging the same core immunotherapy platform.

Risk Factors

Key risks include early-stage clinical trial failure, the need for significant additional capital to fund development, and intense competition in the broader HER2 oncology market from well-funded pharmaceutical companies with approved therapies.

Competitive Landscape

Faces limited direct competition in osteosarcoma but will compete with standard chemotherapy. In broader HER2+ cancers, competes with major players like Roche (Herceptin, Kadcyla, Enhertu*) and AstraZeneca/Daiichi Sankyo (Enhertu). Differentiation relies on a unique immune-activating mechanism versus existing targeted therapies and ADCs. *Note: Enhertu (trastuzumab deruxtecan) is jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.